Drug Profile
Pembrolizumab biosimilar - Sandoz
Alternative Names: GME-751Latest Information Update: 10 Feb 2024
Price :
$50
*
At a glance
- Originator Sandoz
- Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Malignant melanoma; Non-small cell lung cancer
Most Recent Events
- 07 Dec 2023 Sandoz plans a phase III trial for Non small cell lung cancer (Metastatic disease, First line therapy, Combination therapy)in February 2024 (NCT06159790)
- 01 Dec 2023 Preclinical trials in Malignant melanoma in Germany (IV)
- 01 Dec 2023 Preclinical trials in Non-small cell lung cancer in Germany (IV)